Eliquis Clinical Development
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
A timeline chronicling the development history of Bristol-Myers Squibb/Pfizer’s apixaban.
You may also be interested in...
Eliquis Approval Delayed By Fraud In China, Dispensing Errors In Pivotal Trial
Despite expectations that Bristol-Myers Squibb/Pfizer’s novel oral anticoagulant apixaban would sail through U.S. FDA on the strength of the superior efficacy and safety compared to warfarin in the ARISTOTLE trial, study conduct issues led to a nine-month delay in approval.
Eliquis Approval Delayed By Fraud, Dispensing Errors In Pivotal Trial
Despite expectations that Bristol-Myers Squibb/Pfizer’s novel oral anticoagulant apixaban would sail through FDA on the strength of the superior efficacy and safety compared to warfarin in the ARISTOTLE trial, study conduct issues led to a nine-month delay in approval.
Eliquis Approval Delayed By Fraud, Dispensing Errors In Pivotal Trial
Despite expectations that Bristol-Myers Squibb/Pfizer’s novel oral anticoagulant apixaban would sail through FDA on the strength of the superior efficacy and safety compared to warfarin in the ARISTOTLE trial, study conduct issues led to a nine-month delay in approval.